In a bid to address the escalating threat of antibiotic-resistant infections, infectious disease experts are urging the Australian government to implement a Netflix-style subscription model for new antibiotics. This call to action comes ahead of a global superbug summit set to take place in Sydney this week.
Currently, superbugs are responsible for an estimated 5,200 deaths annually in Australia, with over 1,600 directly attributed to antimicrobial resistance (AMR). Projections indicate that by 2050, this figure could rise to 10,000 deaths annually in Australia alone, while globally, AMR could claim 10 million lives if not effectively managed.
The Growing Threat of Superbugs
Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites evolve to resist the effects of antibiotics, rendering common treatments ineffective. This poses a significant risk to public health, as routine surgeries and minor injuries could become life-threatening without effective antibiotics. The Australian Centre for Disease Control (ACDC) has recently highlighted AMR as one of the most urgent public health threats facing the nation and the world.
Reports show that critical antibiotic resistance in Australia increased by more than 25% in 2024, with multidrug-resistant bacteria present in 12.2% of bloodstream infections in children. This alarming trend underscores the need for immediate action to prevent further escalation.
Case Study: The Human Impact
Lyn Barker, a 68-year-old retired midwife, has been battling a superbug infection known as Carbapenem-resistant Gram-negative bacteria (CR-GNB) for two years. What began as a minor callus on her foot developed into a severe wound, requiring toxic intravenous antibiotics only available at The Alfred Hospital. Despite the grueling treatment, Barker managed to save her foot from amputation.
“It was really difficult, but I saved my foot,” Barker said. “They had talked about amputation. I’m still trying to heal up the wound.”
Her experience highlights the personal toll of AMR and the urgent need for new treatment options.
Proposed Solutions: A Subscription Model
The Australian Antimicrobial Resistance Network (AAMRNet) is advocating for a subscription model where the government would pay pharmaceutical companies a fixed annual fee for access to novel antibiotics, regardless of their usage. This approach aims to incentivize pharmaceutical companies to invest in the research and development of new antibiotics.
The United Kingdom has already adopted a similar model, with the NHS paying between £5 million ($9.6 million) and £20 million per drug per year. This initiative has secured access to two new antibiotics, Cefiderocol and Ceftazidime-avibactam, which are crucial in treating severe, multidrug-resistant infections.
“This ‘Netflix-style approach’ addresses a market failure,” said Dame Professor Sally Davies, UK Special Envoy on AMR. “We need big companies manufacturing new antibiotics. If we get this right and other countries join in, then it will reactivate the whole industry in this field.”
Challenges and Considerations
While the subscription model presents a promising solution, experts like Associate Professor Phoebe Williams emphasize the need for rigorous stewardship to preserve the effectiveness of new antibiotics. Williams, a paediatrician and infectious disease physician, has witnessed the increasing frequency of superbug cases in neonatal intensive care units, where access to suitable antibiotics is often limited.
“Antimicrobial resistance is evolving faster than we can come up with medications to treat these multidrug-resistant bugs,” Williams said. “In children, the problem is exacerbated; we have even less access to new antibiotics that are only licensed for adult patients.”
Her experiences underline the importance of ensuring that new antibiotics are not only developed but also appropriately managed to prevent further resistance.
Looking Ahead
The upcoming Global AMR Summit in Sydney, hosted by CSIRO and the UK Fleming Initiative, will serve as a platform for discussing these challenges and potential solutions. Experts hope that the summit will galvanize international cooperation and commitment to combating AMR through innovative models like the proposed subscription approach.
As the world grapples with the rising threat of superbugs, the need for effective strategies and international collaboration has never been more critical. The proposed subscription model represents a significant step forward in addressing this global health crisis.
